Swedish Orphan Biovitrum (Sobi) and Innate Pharma have formed a strategic partnership to initiate the TELLOMAK-3 Phase 3 trial for lacutamab, targeting cutaneous T-cell lymphoma (CTCL), including Sézary syndrome. This trial is a key step toward accelerated approval and eventual full approval of lacutamab, a novel antibody treatment. Sobi will gain exclusive global commercialization rights upon approval and may assume full development rights after positive Phase 3 results. The deal includes upfront and milestone payments to Innate Pharma, supporting the advancement of this rare disease therapy globally.
FLSmidth & Co. A/S continued its share buy-back program initiated on 18 May 2026, repurchasing 61,000 shares between 3 and 7 August 2026 at prices ranging from DKK 487.45 to DKK 511.77 per share. This brings the total shares bought back under the pro...
Jyske Bank is conducting a share buyback program from February 5, 2026, to January 29, 2027, with a maximum value of DKK 3 billion. As of early August 2026, the bank has repurchased shares worth approximately DKK 1.57 billion at an average price of D...
Jyske Bank has continued its share repurchase program initiated in February 2026, acquiring shares valued at approximately DKK 1.57 billion by early August 2026. The program, which runs until January 29, 2027, allows the bank to buy back shares up to...
Quadient has been named among the leading providers in The Forrester Wave™: Accounts Payable Invoice Automation Software, Q2 2026, marking its first inclusion in this key industry evaluation. The recognition highlights Quadient's growing presence and...
Oil and natural gas markets are closely watching developments around the Strait of Hormuz, where negotiations to ease shipping tensions offer hope but ongoing attacks and restrictions keep supply risks high. Crude oil imports to Asia, especially Chin...
